List view / Grid view
12 June 2015 | By
Celgene International has announced updated results of its pivotal Phase III FIRST trial of REVLIMID at the European Haematology Association annual congress...
12 June 2015 | By Victoria White
Novartis has presented promising data from the Phase III COMPLEMENT 2 study of Arzerra in patients with replapsed chronic lymphocytic leukaemia...
12 June 2015 | By Victoria White
New analyses from pivotal Phase III studies show Xolair helps patients with Chronic Spontaneous Urticaria achieve improvements in quality of life measures...
12 June 2015 | By Victoria White
Top line results from a Phase 3 study evaluating Pristiq in paediatric patients with Major Depressive Disorder (MDD) have been announced...
12 June 2015 | By Victoria White
ORYX's Phase I/IIa trial assessing oncolytic parvovirus H1 as a treatment for patients with glioblastoma multiforme has been successfully completed...
11 June 2015 | By Victoria White
Capita Healthcare Decisions has won a contract with Healthdirect Australia to help people check their symptoms online and receive healthcare advice...
11 June 2015 | By Victoria White
The first patient in Singapore has been treated with TheraSphere radioembolization therapy- a treatment for primary liver cancer and metastatic bowel cancer...
11 June 2015 | By Victoria White
Celyad has completed the 30-day safety follow-up of the first patient enrolled in a Phase I clinical trial evaluating the safety of NKG2D CAR T-cell therapy..
11 June 2015 | By Victoria White
Merck Serono has announced that the product design of its fertility pens won over the 38-member jury of the Red Dot Award: Product Design 2015...
11 June 2015 | By Victoria White
Seventeen Janssen Immunology abstracts in ankylosing spondylitis, rheumatoid arthritis, psoriatic arthritis and psoriasis, will be presented at EULAR...
11 June 2015 | By Victoria White
The results of a study presented at EULAR 2015 show that NSAIDs, such as diclofenac, significantly inhibit ovulation in women with mild musculoskeletal pain...
11 June 2015 | By Victoria White
Trials fail to measure how a drug’s performance can vary based on patient behaviour, especially if patients change habits in anticipation of treatment...
11 June 2015 | By Victoria White
The global market value for axial spondyloarthritis therapeutics will expand from $1.5 billion in 2014 to reach $2.9 billion by 2024...
11 June 2015 | By Victoria White
Healthcare firms have to be prepared to break with tradition and move away from employing a one-size-fits-all approach with existing suppliers...
10 June 2015 | By Victoria White
Results from a pivotal Phase 3 study of HUMIRA demonstrate significant and clinically meaningful efficacy in children and adolescents with plaque psoriasis...
